ADRICN(Epirubicin)
Therapeutic class: anthracycline topoisomerase II inhibitor
Indication: Primary Breast Cancer
- 10 mg/5ml & 50 mg/25ml injection
- 2°C to 8°C, Shelf Life: 2 Years
- As directed by physician
